Key Highlights:
- Aitia and Europe’s top cancer institute, Gustave Roussy, partner to create AI-powered Gemini Digital Twins to uncover root causes of cancer.
- Causal AI models will analyze vast multiomic datasets to identify novel drug targets and guide clinical development for hard-to-treat cancers.
- Collaboration aims to transform cancer outcomes globally by unlocking the biological mechanisms behind >200 cancer types.
AI Collaboration to Decode Cancer Complexity
In a bold step to redefine cancer treatment, Aitia, a leader in causal AI for drug discovery, has announced a strategic partnership with Gustave Roussy, Europe’s foremost cancer research center. The collaboration focuses on deploying Aitia’s Gemini Digital Twins—computational disease models built from real-world multiomic and clinical data—to uncover the fundamental causes of multiple human cancers. This initiative aims to accelerate the discovery of transformative treatments by identifying biologically validated drug targets in complex and currently untreatable cancers.
Harnessing Gemini Digital Twins for Drug Discovery
At the heart of the collaboration is Aitia’s causal AI platform, REFS®, which will be used to convert Gustave Roussy’s extensive de-identified patient data into in silico disease models. These Gemini Digital Twins replicate the biological behavior of patients, allowing researchers to predict causal mechanisms, identify optimal drug combinations, and define responder subpopulations for targeted therapies. The goal is to cut down on drug development time, reduce costs, and improve precision in oncology treatments.
Gustave Roussy’s Data Advantage and Research Excellence
With nearly 50,000 cancer patients treated annually and 40% of them enrolled in clinical studies, Gustave Roussy brings unparalleled depth in multiomic data and research leadership. As a founding member of the Paris Saclay Cancer Cluster and Europe’s #1 cancer center, the institution is poised to drive innovation at the convergence of AI, oncology, and patient-centered care. This partnership expands Gustave Roussy’s digital research capabilities and supports its mission to pioneer new diagnostic and therapeutic strategies.
Transforming Global Oncology with AI and Collaboration
Both organizations are united by a shared mission to improve cancer outcomes worldwide. This collaboration marks a significant milestone in AI-driven oncology innovation. By jointly leveraging data, domain expertise, and advanced computational platforms, Aitia and Gustave Roussy aim to reshape the future of cancer drug development—ushering in a new era of causality-based, personalized medicine for some of the most challenging diseases affecting humanity.
About Aitia
Aitia is a computational biotech company advancing drug discovery through causal AI. Its proprietary REFS® platform creates Gemini Digital Twins of human disease, uncovering root biological mechanisms to identify new targets, biomarkers, and therapeutics. Visit www.aitia.com
About Gustave Roussy
Gustave Roussy is Europe’s leading cancer center, ranked 4th globally, offering comprehensive cancer care, research, and education. The center treats rare and complex cancers and integrates cutting-edge science with personalized care. Learn more at www.gustaveroussy.fr/en
By
